(Q33683120)

English

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

9

object named as

J Jassem

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

H Bonnefoi

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

S Litière

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

M Piccart

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

G MacGrogan

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

P Fumoleau

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

E Brain

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

T Petit

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

P Rouanet

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

C Moldovan

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

A Bodmer

11

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

K Zaman

12

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

T Cufer

13

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

M Campone

14

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

E Luporsi

15

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

P Malmström

16

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

G Werutsky

17

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

J Bogaerts

18

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

J Bergh

19

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

D A Cameron

20

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

EORTC 10994/BIG 1-00 Study investigators

21

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

11 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1128-1136

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Challenges of guarantee-time bias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Metastatic behavior of breast cancer subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4037859

21 June 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU118

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU118

21 January 2018

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU118

21 January 2018

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

1 reference

https://pubmed.ncbi.nlm.nih.gov/24618153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24618153

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDU118

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33683120&oldid=1956238984"